Literature DB >> 30411298

MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Gábor Lendvai1, Tímea Szekerczés2, Benedek Gyöngyösi2, Krisztina Schlachter3, Endre Kontsek2, Adrián Pesti2, Attila Patonai4, Klára Werling5, Ilona Kovalszky6, Zsuzsa Schaff2, András Kiss2.   

Abstract

The liver disease focal nodular hyperplasia (FNH) has several histological features that resemble hepatic cirrhosis. Since cirrhosis may develop further into hepatocellular carcinoma (HCC) contrary to FNH, the aim of the present study was to identify microRNAs (miRNA), which, by their altered expression levels, may be associated with the benign, tumor-like nature of FNH. Altogether 106 surgically removed formalin-fixed paraffin-embedded liver samples were selected, including 22 FNH, 45 cirrhosis, 24 HCC and 15 normal liver tissues. Etiology of the cases of cirrhosis and HCC includes hepatitis C and alcoholism and the HCC cases developed in cirrhotic livers. Relative expression levels of 14 miRNAs were determined using TaqMan MicroRNA Assays. In comparison to normal liver, the levels of miR-34a and miR-224 were elevated not only in FNH but also in cirrhosis and HCC, while the expression of miR-17-5p, miR-18a and miR-210 was decreased in FNH. Further, the levels of miR-21 and miR-222 were increased in cirrhosis and HCC but were decreased in FNH and the expression of miR-17-5p, miR-18a, miR-195 and miR-210 was decreased in FNH as compared with cirrhosis and/or HCC. In conclusion, the elevation of miR-34a and miR-224 may be associated with both benign and malignant proliferative processes, nevertheless the increased expression of oncomiRs miR-21 and miR-222 in cirrhosis and HCC but not in FNH may be related to malignant processes of the liver. The decreased levels of miR-18a, miR-195 and miR-210 may further differentiate FNH from cirrhosis, reflecting the different pathogenesis of these two entities contrary to some histologically similar features.

Entities:  

Keywords:  Chronic hepatitis C; Focal nodular hyperplasia; Hepatic cirrhosis; Hepatocellular carcinoma; microRNA

Mesh:

Substances:

Year:  2018        PMID: 30411298     DOI: 10.1007/s12253-018-0528-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  56 in total

1.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

Authors:  Y Murakami; T Yasuda; K Saigo; T Urashima; H Toyoda; T Okanoue; K Shimotohno
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

Review 2.  MicroRNAs in hepatic pathophysiology.

Authors:  Yoshiki Murakami; Norifumi Kawada
Journal:  Hepatol Res       Date:  2016-06-04       Impact factor: 4.288

3.  MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.

Authors:  Tomohiro Ogawa; Masaru Enomoto; Hideki Fujii; Yumiko Sekiya; Katsutoshi Yoshizato; Kazuo Ikeda; Norifumi Kawada
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

Review 4.  MiR-122 in hepatic function and liver diseases.

Authors:  Jun Hu; Yaxing Xu; Junli Hao; Saifeng Wang; Changfei Li; Songdong Meng
Journal:  Protein Cell       Date:  2012-05-18       Impact factor: 14.870

5.  miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling.

Authors:  Donglai Ma; Xuanchen Tao; Feng Gao; Chengjuan Fan; Dequan Wu
Journal:  Oncol Lett       Date:  2012-06-07       Impact factor: 2.967

Review 6.  Review article: the reversibility of cirrhosis.

Authors:  A A Sohrabpour; M Mohamadnejad; R Malekzadeh
Journal:  Aliment Pharmacol Ther       Date:  2012-11       Impact factor: 8.171

7.  Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.

Authors:  Claus Lindbjerg Andersen; Jens Ledet Jensen; Torben Falck Ørntoft
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 8.  Management of end-stage liver disease.

Authors:  Iris W Liou
Journal:  Med Clin North Am       Date:  2013-10-30       Impact factor: 5.456

9.  Circulating microRNAs as markers of liver inflammation, fibrosis and cancer.

Authors:  Christoph Roderburg; Tom Luedde
Journal:  J Hepatol       Date:  2014-10-11       Impact factor: 25.083

Review 10.  Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma.

Authors:  Massimo Roncalli; Amedeo Sciarra; Luca Di Tommaso
Journal:  Clin Mol Hepatol       Date:  2016-05-18
View more
  2 in total

1.  Giant focal nodular hyperplasia with a background of hepatic steatosis in a 14-year-old boy.

Authors:  Andrew M Fleming; Caitlyn Duffy; Jessica Gartrell; M Beth McCarville; Max R Langham; Robert E Ruiz; Teresa Santiago; Andrew J Murphy
Journal:  J Surg Case Rep       Date:  2022-05-27

2.  Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis.

Authors:  Rui Zhang; Ying-Yi Jiang; Kun Xiao; Xiao-Quan Huang; Jian Wang; Shi-Yao Chen
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-22       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.